title: HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes.
abstract: Patients with type 2 diabetes are known to have abnormalities in their remnant metabolism and low density lipoprotein (LDL) subfraction pattern, with a preponderance of small dense LDL. The effects of pitavastatin, a newly synthesized 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, on lipoprotein profiles in patients with type 2 diabetes were determined. Thirty-three patients were treated with pitavastatin with a daily dose of 2 mg for 8 weeks. After treatment, triglyceride, total and LDL cholesterol were significantly reduced by 28.7 +/- 36.7%, 25.2 +/- 14.3% and 36.1 +/- 14.3%, respectively. Remnant-like particle cholesterol (RLP-C), an independent risk factor for CAD which is known to be elevated in diabetic patients, was also significantly reduced (-30.9 +/- 30.5%) by the treatment and this decrease correlated well with the decrease in triglyceride level. The proportion of small dense LDL, which is known for its atherogenisity, decreased from 29.9 +/- 26.2% to 19.7 +/- 22.7% and the mean LDL particle size significantly increased from 26.36 +/- 1.13 nm to 27.10 +/- 1.36 nm. Pitavastatin, which is known to improve triglyceride levels and cholesterol levels, also improves RLP-C level and LDL subfraction profiles, and this in turn may reduce the cardiovascular risk in patients with type 2 diabetes and dyslipidemia.
authors.affiliation: Department of Internal Medicine (Endocrinology/Metabolism), Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
authors.forename: Hirohito
authors.initials: H
authors.lastname: Sone
authors.forename: Akimitsu
authors.initials: A
authors.lastname: Takahashi
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Shimano
authors.forename: Shun
authors.initials: S
authors.lastname: Ishibashi
authors.forename: Gen
authors.initials: G
authors.lastname: Yoshino
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Morisaki
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Saito
authors.forename: Shoji
authors.initials: S
authors.lastname: Kawazu
authors.forename: Tamio
authors.initials: T
authors.lastname: Teramoto
authors.forename: Toshiro
authors.initials: T
authors.lastname: Fujita
authors.forename: Teruo
authors.initials: T
authors.lastname: Shiba
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Iwamoto
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Kuzuya
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Akanuma
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yamada
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D002784:Cholesterol